The NeurologyLive® headache and migraine clinical focus page offers information, podcasts, videos, and news and interviews with physicians related to the care of patients with headache disorders such as chronic and episodic migraine, cluster headache, tension-type headache, and more. The page includes updates on the latest FDA actions, clinical guidelines, and study and clinical trial findings.
May 10th 2024
ABP-450, a botulinum toxin type A complex agent, failed to meet either primary or secondary end points in a cohort of 325 patients with chronic migraine.
Improving Care for Patients with Motor Complications of Parkinson Disease: Role of Technology and Data
View More
Clinical Consultations™: Considerations for Customizing Care Plans for Patients with Parkinson Disease Psychosis
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
September 15, 2024
Register Now!
Mastering MS: Translating Evidence into Optimal Management Plans
View More
Advances In Treating Migraine in Your OB/GYN Practice: Navigating Treatment Paradigms to Improve Patient Care
View More
Recognizing Rett Syndrome Early to Improve Long-term Management Outcomes
View More
5th Annual International Congress on the Future of Neurology®
View More
Clinical Consultations™: Managing Depressive Episodes in Patients with Bipolar Disorder Type II
View More
Advances In™ Generalized Myasthenia Gravis: Improving Patient Outcomes Through Early Diagnosis and Management
View More
Medical Crossfire®: Understanding the Advances in Bipolar Disease Treatment—A Comprehensive Look at Treatment Selection Strategies
View More
'REEL’ Time Patient Counseling: The Diagnostic and Treatment Journey for Patients With Bipolar Disorder Type II – From Primary to Specialty Care
View More
Burst CME: Optimizing Therapy in Parkinson’s Disease
View More
Community Practice Connections™: Transforming Multiple Sclerosis Care – Clinical Updates on the Effects of BTK Inhibitors
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of the Complement Pathway in Neurological Disorders
View More
Burst Expert Illustrations & Commentary™ : Visualizing the Role of the Complement Proteins in Neurologic Disorders
View More
Burst Expert Illustrations & Commentary™: Visualizing the Implications of Anti-Complement Therapies on Generalized Myasthenia Gravis
View More
Addressing Healthcare Inequities: Bridging the Gap in Multiple Sclerosis – A Focus on Clinical and Healthcare Disparities in Black Patients
View More
Individualizing Treatment for Patients with Generalized Myasthenia Gravis
View More
Patient, Provider & Caregiver Connection™: Reducing the Burden of Parkinson Disease Psychosis with Personalized Management Plans
View More
Clinical ShowCase™ in ALS: Addressing Diagnostic Delays, Evolving Therapies, and Multidisciplinary Care
View More
Triptan Use Shows No Significant Vascular Comorbidity Increase for Older Patients With Migraine
July 1st 2022In triptan users, prescriptions of cardiac therapies and beta blockers were significantly more common compared with other prescriptions of calcium channel blockers and renin/angiotensin inhibitors, which were significantly less common.
AbbVie Submits Supplemental New Drug Application for Atogepant in Chronic Migraine
June 22nd 2022Originally approved for the preventive treatment of episodic migraine in Sept 2021, atogepant’s potential new indication stems from positive results from the double-blind, placebo-controlled, phase 3 PROGRESS trial.
New Treatments in Migraine: An In-Depth Review
June 16th 2022Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.
Tremeau Pharmaceuticals Gets IND Go-Ahead for Rofecoxib Reformulation, Dubbed TRM-201
June 15th 2022The oral tablet formulation of rofecoxib has been shown to reach maximum plasma concentrations at 2 hours post dose compared with 3 for the historical formulation, which the company believes can improve the time to onset of action.
The Effect of Mindfulness Practices on Migraine: Paige Estave, PhD
June 15th 2022The MD-PhD student at Wake Forest School of Medicine shared her perspective on the findings of a study suggesting that mindfulness practices can alter pain perception and migraine attack awareness, among other results. [WATCH TIME: 4 minutes]
Children, Adolescents With Migraine Show High Risk for Anxiety and Depression Symptoms
June 14th 2022A systematic review and meta-analysis suggested that the risk of anxiety and depressive symptoms was nearly doubled for those with migraine compared with healthy controls, indicating a need to screen this patient population.
The Endocannabinoid System and its Relationship to Migraine: Tally Largent-Milnes, PhD
June 13th 2022The assistant professor of pharmacology at the University of Arizona College of Medicine Tucson shared her insight into the endocannabinoid system and its therapeutic potential in treating migraine. [WATCH TIME: 5 minutes]
Neuronal Complexity in a Model of Migraine: Amynah Pradhan, PhD
June 12th 2022The associate professor of psychiatry at the University of Illinois at Chicago shared the findings of her and colleagues’ work that suggest that distinct cytoarchitectural changes occur in the brain that may underlie migraine chronification. [WATCH TIME: 4 minutes]
Anxiety and Depression in Children and Adolescents With Migraine: Serena L. Orr, MD, MSc
June 12th 2022The pediatric neurologist and headache specialist at the University of Calgary discussed the work she presented at AHS 2022 on the incidence of anxiety and depressive disorders in the pediatric migraine population. [WATCH TIME: 6 minutes]
Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence
June 11th 2022Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.